Armstrong DK

ORCID: 0000-0003-0852-803X · 4 papers in corpus · active 2009-2019
2019
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
The New England journal of medicine ·doi:10.1056/nejmoa1902626

BackgroundSecondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated in phase 3 investigation.Meth…

2017
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
Gynecologic Oncology ·doi:10.1016/j.ygyno.2017.08.004

PurposeWe examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC).MethodsWe reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who participate…

2011
Recent progress in the diagnosis and treatment of ovarian cancer.
CA: a cancer journal for clinicians ·doi:10.3322/caac.20113

Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and the cancer antigen (CA) 125 tumor marker are currently …

2009
A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.
Gynecologic Oncology ·doi:10.1016/j.ygyno.2009.06.021

ObjectiveSerum CA-125 values have been advocated in the monitoring of ovarian cancer patients receiving intravenous (IV) chemotherapy. This evaluation sought to determine if the CA-125 test can be used to monitor treatment effect among pati…